Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases
Brain metastases are an increasing burden among breast cancer patients, particularly for those with HER2+ and triple negative (TN) subtypes. Mechanistic insight into the pathophysiology of brain metastases and preclinical validation of therapies has relied almost exclusively on intracardiac injectio...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fonc.2017.00252/full |
| _version_ | 1818524769741438976 |
|---|---|
| author | María J. Contreras-Zárate D. Ryan Ormond Austin E. Gillen Colton Hanna Nicole L. Day Natalie J. Serkova Britta M. Jacobsen Susan M. Edgerton Ann D. Thor Virginia F. Borges Kevin O. Lillehei Michael W. Graner Peter Kabos Diana M. Cittelly |
| author_facet | María J. Contreras-Zárate D. Ryan Ormond Austin E. Gillen Colton Hanna Nicole L. Day Natalie J. Serkova Britta M. Jacobsen Susan M. Edgerton Ann D. Thor Virginia F. Borges Kevin O. Lillehei Michael W. Graner Peter Kabos Diana M. Cittelly |
| author_sort | María J. Contreras-Zárate |
| collection | DOAJ |
| description | Brain metastases are an increasing burden among breast cancer patients, particularly for those with HER2+ and triple negative (TN) subtypes. Mechanistic insight into the pathophysiology of brain metastases and preclinical validation of therapies has relied almost exclusively on intracardiac injection of brain-homing cells derived from highly aggressive TN MDA-MB-231 and HER2+ BT474 breast cancer cell lines. Yet, these well characterized models are far from representing the tumor heterogeneity observed clinically and, due to their fast progression in vivo, their suitability to validate therapies for established brain metastasis remains limited. The goal of this study was to develop and characterize novel human brain metastasis breast cancer patient-derived xenografts (BM-PDXs) to study the biology of brain metastasis and to serve as tools for testing novel therapeutic approaches. We obtained freshly resected brain metastases from consenting donors with breast cancer. Tissue was immediately implanted in the mammary fat pad of female immunocompromised mice and expanded as BM-PDXs. Brain metastases from 3/4 (75%) TN, 1/1 (100%) estrogen receptor positive (ER+), and 5/9 (55.5%) HER2+ clinical subtypes were established as transplantable BM-PDXs. To facilitate tracking of metastatic dissemination using BM-PDXs, we labeled PDX-dissociated cells with EGFP-luciferase followed by reimplantation in mice, and generated a BM-derived cell line (F2-7). Immunohistologic analyses demonstrated that parental and labeled BM-PDXs retained expression of critical clinical markers such as ER, progesterone receptor, epidermal growth factor receptor, HER2, and the basal cell marker cytokeratin 5. Similarly, RNA sequencing analysis showed clustering of parental, labeled BM-PDXs and their corresponding cell line derivative. Intracardiac injection of dissociated cells from BM-E22-1, resulted in magnetic resonance imaging-detectable macrometastases in 4/8 (50%) and micrometastases (8/8) (100%) mice, suggesting that BM-PDXs remain capable of colonizing the brain at high frequencies. Brain metastases developed 8–12 weeks after ic injection, located to the brain parenchyma, grew around blood vessels, and elicited astroglia activation characteristic of breast cancer brain metastasis. These novel BM-PDXs represent heterogeneous and clinically relevant models to study mechanisms of brain metastatic colonization, with the added benefit of a slower progression rate that makes them suitable for preclinical testing of drugs in therapeutic settings. |
| first_indexed | 2024-12-11T06:01:13Z |
| format | Article |
| id | doaj.art-dfb81a61e8cf45c8a8e1061bcd70fabb |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T06:01:13Z |
| publishDate | 2017-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dfb81a61e8cf45c8a8e1061bcd70fabb2022-12-22T01:18:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2017-11-01710.3389/fonc.2017.00252295911Development of Novel Patient-Derived Xenografts from Breast Cancer Brain MetastasesMaría J. Contreras-Zárate0D. Ryan Ormond1Austin E. Gillen2Colton Hanna3Nicole L. Day4Natalie J. Serkova5Britta M. Jacobsen6Susan M. Edgerton7Ann D. Thor8Virginia F. Borges9Kevin O. Lillehei10Michael W. Graner11Peter Kabos12Diana M. Cittelly13Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesRNA Bioscience Initiative, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesBrain metastases are an increasing burden among breast cancer patients, particularly for those with HER2+ and triple negative (TN) subtypes. Mechanistic insight into the pathophysiology of brain metastases and preclinical validation of therapies has relied almost exclusively on intracardiac injection of brain-homing cells derived from highly aggressive TN MDA-MB-231 and HER2+ BT474 breast cancer cell lines. Yet, these well characterized models are far from representing the tumor heterogeneity observed clinically and, due to their fast progression in vivo, their suitability to validate therapies for established brain metastasis remains limited. The goal of this study was to develop and characterize novel human brain metastasis breast cancer patient-derived xenografts (BM-PDXs) to study the biology of brain metastasis and to serve as tools for testing novel therapeutic approaches. We obtained freshly resected brain metastases from consenting donors with breast cancer. Tissue was immediately implanted in the mammary fat pad of female immunocompromised mice and expanded as BM-PDXs. Brain metastases from 3/4 (75%) TN, 1/1 (100%) estrogen receptor positive (ER+), and 5/9 (55.5%) HER2+ clinical subtypes were established as transplantable BM-PDXs. To facilitate tracking of metastatic dissemination using BM-PDXs, we labeled PDX-dissociated cells with EGFP-luciferase followed by reimplantation in mice, and generated a BM-derived cell line (F2-7). Immunohistologic analyses demonstrated that parental and labeled BM-PDXs retained expression of critical clinical markers such as ER, progesterone receptor, epidermal growth factor receptor, HER2, and the basal cell marker cytokeratin 5. Similarly, RNA sequencing analysis showed clustering of parental, labeled BM-PDXs and their corresponding cell line derivative. Intracardiac injection of dissociated cells from BM-E22-1, resulted in magnetic resonance imaging-detectable macrometastases in 4/8 (50%) and micrometastases (8/8) (100%) mice, suggesting that BM-PDXs remain capable of colonizing the brain at high frequencies. Brain metastases developed 8–12 weeks after ic injection, located to the brain parenchyma, grew around blood vessels, and elicited astroglia activation characteristic of breast cancer brain metastasis. These novel BM-PDXs represent heterogeneous and clinically relevant models to study mechanisms of brain metastatic colonization, with the added benefit of a slower progression rate that makes them suitable for preclinical testing of drugs in therapeutic settings.http://journal.frontiersin.org/article/10.3389/fonc.2017.00252/fullpatient-derived xenograftbrain metastases modelsbreast cancerbrain colonizationtriple negativeHER2+ |
| spellingShingle | María J. Contreras-Zárate D. Ryan Ormond Austin E. Gillen Colton Hanna Nicole L. Day Natalie J. Serkova Britta M. Jacobsen Susan M. Edgerton Ann D. Thor Virginia F. Borges Kevin O. Lillehei Michael W. Graner Peter Kabos Diana M. Cittelly Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases Frontiers in Oncology patient-derived xenograft brain metastases models breast cancer brain colonization triple negative HER2+ |
| title | Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases |
| title_full | Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases |
| title_fullStr | Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases |
| title_full_unstemmed | Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases |
| title_short | Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases |
| title_sort | development of novel patient derived xenografts from breast cancer brain metastases |
| topic | patient-derived xenograft brain metastases models breast cancer brain colonization triple negative HER2+ |
| url | http://journal.frontiersin.org/article/10.3389/fonc.2017.00252/full |
| work_keys_str_mv | AT mariajcontreraszarate developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT dryanormond developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT austinegillen developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT coltonhanna developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT nicolelday developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT nataliejserkova developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT brittamjacobsen developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT susanmedgerton developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT anndthor developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT virginiafborges developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT kevinolillehei developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT michaelwgraner developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT peterkabos developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases AT dianamcittelly developmentofnovelpatientderivedxenograftsfrombreastcancerbrainmetastases |